Amar Patel is a Neurology physician affiliated with Yale University. OpenAlex indexes 59 publications with 816 citations (h-index 15); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Howard Ave Lowr Level
New Haven, CT 065191369
Telephone
203-785-4085Registry record last updated 23 Jun 2015.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20251 payment
- Abbott LaboratoriesProgram year20241 payment
- Medtronic, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
90.8%Aromatic Amino Acid Decarboxylation Inhibitor40.9%Carbidopa-Levodopa67%Rytary17%Carbidopa-Levodopa Er11%Carbidopa-Levodopa-Entacapone4%Duopa1%Part D<11 patientsBenzodiazepine9.6%Clonazepam71%Lorazepam14%Alprazolam8%Diazepam7%Part D<11 patients+ 19 more classes in this area
Cardiovascular
4.6%Beta blocker3.2%Propranolol Hcl Er47%Propranolol Hcl39%Atenolol14%Part D<11 patientsalpha-Adrenergic Agonist1.1%Midodrine Hcl100%Part D≥12 patients+ 1 more class in this area
Musculoskeletal
2.6%gamma-Aminobutyric Acid-ergic Agonist1.2%Baclofen100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist1%Tizanidine Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Return to Golf After Hip Arthroscopy: A Systematic Review of the Literature
Sports Health A Multidisciplinary Approach
2024 - Differential impact of resilience on demoralization and depression in Parkinson disease
Frontiers in Psychiatry
2023
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”